{"transactions":[{"id":1225883,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T22:28:41.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":109309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":109309,"derivative":{"exercise_price":5.31,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":109309},"source":{"system":"sec-edgar","filing":"0000905148-25-000838","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000838/form4.xml","form_type":"4"}},{"id":1258471,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:55:13.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":434,"price":5.42,"value":2352.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":26088,"source":{"system":"sec-edgar","filing":"0000905148-25-000728","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000728/form4.xml","form_type":"4"}},{"id":1348790,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T23:10:12.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":90090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":90090,"derivative":{"exercise_price":5.7,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90090},"source":{"system":"sec-edgar","filing":"0000905148-24-003293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003293/form4.xml","form_type":"4"}},{"id":1361255,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-18T21:30:48.000Z","date":"2024-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":368,"price":7.92,"value":2914.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":26522,"source":{"system":"sec-edgar","filing":"0000905148-24-003226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003226/form4.xml","form_type":"4"}},{"id":1430837,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-16T20:51:16.000Z","date":"2024-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":368,"price":7.02,"value":2583.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":26890,"source":{"system":"sec-edgar","filing":"0000905148-24-002280","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824002280/form4.xml","form_type":"4"}},{"id":1513695,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-16T23:00:26.000Z","date":"2024-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":368,"price":8.36,"value":3076.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":27258,"source":{"system":"sec-edgar","filing":"0000905148-24-001489","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001489/form4.xml","form_type":"4"}},{"id":1637425,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-16T22:12:43.000Z","date":"2024-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":434,"price":3.4,"value":1475.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":27626,"source":{"system":"sec-edgar","filing":"0000905148-24-000763","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824000763/form4.xml","form_type":"4"}},{"id":1738558,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-17T00:42:18.000Z","date":"2023-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1470,"price":5.08,"value":7467.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":28060,"source":{"system":"sec-edgar","filing":"0000905148-23-001475","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514823001475/form4.xml","form_type":"4"}},{"id":1848552,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:21:20.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":false,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on April 20, 2023, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":183119,"derivative":{"exercise_price":3.63,"expiration_date":"2032-06-28","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001140361-23-030544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123030544/form4.xml","form_type":"4"}},{"id":1848551,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:21:20.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":true,"shares":9500,"price":3.63,"value":34485.0,"ownership":{"direct":true},"balance_after":29530,"source":{"system":"sec-edgar","filing":"0001140361-23-030544","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123030544/form4.xml","form_type":"4"}},{"id":2114017,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T00:13:18.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":60090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":60090,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":60090},"source":{"system":"sec-edgar","filing":"0001209191-22-057398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057398/doc4.xml","form_type":"4"}},{"id":2114016,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":82409,"kind":"person","name":"Holm-Jorgensen Rasmus","position":1,"cik":"0001950496","reported_name":"Holm-Jorgensen Rasmus","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-17T00:13:18.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":20030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":20030,"source":{"system":"sec-edgar","filing":"0001209191-22-057398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057398/doc4.xml","form_type":"4"}}]}